Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Blood blood.2024025454.

https://doi.org/10.1182/blood.2024025454

Published: 2024

Includes: Supplemental data

Journal Articles

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Yuqin Song, Zengjun Li, Ling Li, Zhengzi Qian, Keshu Zhou, Lei Fan, Peter Tan, Pratyush Giri, Zhiming Li, Melita Kenealy, Jie Jin, Wei Liu, Shafqat Inam, Yan Xie, Xia Guo, Wenduo He, Raymond Xu, Tong Li, Jun Zhu

Blood (2023) 142 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2023-188444

Published: 2023

Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Blood (2023) 142 (Supplement 1): 603.

https://doi.org/10.1182/blood-2023-173692

Published: 2023

Journal Articles

Australasian Leukaemia & Lymphoma Group NHL35-Pacific: An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma - Trial in Progress

Katharine L. Lewis, Piers Blombery, Nagendra Prasad Sungala, Chun Kei Kris Ma, Pratyush Giri, Vinay Vanguru, Tara Cochrane, Joanna Katarzyna Czerwinski, Denise Lee, Nada Hamad, Roslyn Francis, Mannu Walia, Julia Carlson, Belinda E Butcher, Chan Y. Cheah

Blood (2023) 142 (Supplement 1): 3103.

https://doi.org/10.1182/blood-2023-185160

Published: 2023

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

Chan Y. Cheah, Sarit Assouline, Ross Baker, Nancy L. Bartlett, Dima El-Sharkawi, Pratyush Giri, Matthew Ku, Stephen J. Schuster, Matthew Matasar, John Radford, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 614.

https://doi.org/10.1182/blood-2023-173796

Published: 2023

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Blood (2023) 141 (9): 1087–1091.

https://doi.org/10.1182/blood.2022018236

Published: 2023

Includes: Supplemental data

Journal Articles

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Blood (2022) 140 (Supplement 1): 3753–3755.

https://doi.org/10.1182/blood-2022-157729

Published: 2022

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Huang Huang, Juliana Min, Elicia Penuel, L. Elizabeth Budde

Blood (2022) 140 (Supplement 1): 1467–1470.

https://doi.org/10.1182/blood-2022-157691

Published: 2022

Journal Articles

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Yuqin Song, Ning Ding, Dok Hyun Yoon, John C. Reneau, Ryan A. Wilcox, Won Seog Kim, Youn H. Kim, Michael S. Khodadoust, Tatyana A. Feldman, Costas K. Yannakou, Pratyush Giri, Jonathan E Brammer, Lih-Yun Hsu, Hongwei Yuan, Erik Verner, Suresh Mahabhashyam, Richard A. Miller

Blood (2022) 140 (Supplement 1): 8857–8859.

https://doi.org/10.1182/blood-2022-159177

Published: 2022

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Blood (2021) 138 (Supplement 1): 127.

https://doi.org/10.1182/blood-2021-145872

Published: 2021

Journal Articles

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Blood (2021) 138 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2021-147937

Published: 2021

Journal Articles

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-135818

Published: 2020

Journal Articles

An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome

Angela Molga, MBBS, Michelle Wall, Dip HE (Nursing), BA (Hons), MSc, PG Cert, Rakchha Chhetri, MBBS, Amilia Wee, BSc (Hons), Deepak Singhal, MBBS, MDFRACP, FRCPA, Pratyush Giri, MBBS,FRACP,FRCPA, Timothy To, BSc, BMBS, FRACP, FAChPM, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 5426.

https://doi.org/10.1182/blood-2019-132164

Published: 2019

Journal Articles

Geriatric Assessment in Older People with Myelodysplasia Is Predictive of Azacitidine Therapy Completion and Survival: A Prospective Interventional Study at the Royal Adelaide Hospital

Angela Molga, MBBS, FRACP, Michelle Wall, Dip HE (Nursing), BA (Hons), MSc, PG Cert, Rakchha Chhetri, MBBS, Amilia Wee, BSc (Hons), Deepak Singhal, MBBS, MD FRACP, FRCPA, Nimit Singhal, MBBS MDDM FRACP, David M Ross, Luen Bik To, MBBS, FRACP, FRCPA, PhD, Peter G Bardy, MBBS, FRACP, FRCPA, FRCPath, Pratyush Giri, MBBS, FRACP, FRCPA, Gillian Caughey, PhD, Sepehr Shakib, MBBS, FRACP, PhD, Timothy To, BSc, BMBS, FRACP, FAChPM, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2018) 132 (Supplement 1): 3101.

https://doi.org/10.1182/blood-2018-99-117853

Published: 2018

Journal Articles

Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms

Christopher N Hahn, PhD, Amilia Wee, BSc (Hons), Milena Babic, BMPharBio (Hons), Jinghua Feng, PhD, Paul Wang, Monika M Kutyna, MSc, Sarah Moore, BSc (Hon), FFSc (RCPA), Anna L Brown, PhD, Richard D'Andrea, BSc,PhD, Deepak Singhal, MBBS, MD FRCPA, FRACP, Andreas Schreiber, PhD, Pratyush Giri, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Hamish S Scott, BSc, PhD FFSc (RCPA), FAHMS

Blood (2017) 130 (Supplement 1): 492.

https://doi.org/10.1182/blood.V130.Suppl_1.492.492

Published: 2017

Journal Articles

A Phase III Efficacy and Safety Study of the Proposed Rituximab Biosimilar GP2013 Versus Rituximab in Patients with Previously Untreated Advanced Follicular Lymphoma

Wojciech Jurczak, Moreira Ilidia, Kanaka Setty Govindbabu, Munhoz Eduardo, Echeveste Maria Ascuncion, Pratyush Giri, Castro Nelson, Pereira Juliana, Akria Luiza, Alexeev Sergey, Osmanov Dzhelil, Philippe Pultar, Azzeddine Cherfi, Peijuan Zhu, Jutta Amersdorffer

Blood (2016) 128 (22): 1809.

https://doi.org/10.1182/blood.V128.22.1809.1809

Published: 2016

Journal Articles

Comparison of 2 Doses of Intravenous (IV) Temsirolimus (Temsr) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Wojciech Jurczak, MD, Sundra Ramanathan, MBBS FRCPA FRACP, Pratyush Giri, MBBS, FRACP, FRCPA, Francesco Di Raimondo, MD, Heidi Mocikova, MD, PhD, Jill Clancy, Mariajose Lechuga, MD, Michelle Casey, PhD, Joseph P Boni, PhD, Agnieszka Giza, MD, Georg Hess, MD

Blood (2016) 128 (22): 1775.

https://doi.org/10.1182/blood.V128.22.1775.1775

Published: 2016

Journal Articles

RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry

Deepak Singhal, MD FRCPA, Sophia Hague, BAppSc (MDc), David Roxby, MAppSc AFRCPA FFSc[RCPA], L Amilia Wee, BSc(Hons), Oi-Lin Lee, MBBS, FRCPA, Romi Sinha, MBBS, MIBMS, FACHI, Rakchha Chhetri, MBBS, James X Gray, MBBS, FRACP, FRCPA, MD PhD, Pratyush Giri, MBBS, FRACP, FRCPA, Kathryn Robinson, MBBS, FRACP, FRCPA, Shriram Nath, MBBS, DM, FRCPA, Nicholas Wickham, FRCPA,FRACP,FRCPath, Chi-hung Hui, MBBS, MRCP, FRCPath, FRACP, FRCPA, David T Yeung, BSc, MBBS, FRACP, FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA, Ian D Lewis, MBBS, PhD FRACP, FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, L Bik To, MBBS, FRACP, FRCPA, PhD, Devendra K Hiwase, MBBS, FRACP, FRCPA, MD PhD

Blood (2015) 126 (23): 3562.

https://doi.org/10.1182/blood.V126.23.3562.3562

Published: 2015

NARROW

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Australasian Leukaemia & Lymphoma Group NHL35-Pacific: An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma - Trial in Progress

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome

Geriatric Assessment in Older People with Myelodysplasia Is Predictive of Azacitidine Therapy Completion and Survival: A Prospective Interventional Study at the Royal Adelaide Hospital

Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms

A Phase III Efficacy and Safety Study of the Proposed Rituximab Biosimilar GP2013 Versus Rituximab in Patients with Previously Untreated Advanced Follicular Lymphoma

Comparison of 2 Doses of Intravenous (IV) Temsirolimus (Temsr) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)

RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only